antibody-targeted therapy conjugate

GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers.

By Frank Vinluan

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

Automation Didn’t Dehumanize Care. Bad Systems Did.

We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

Where Will AI Deployment Benefit Payers the Most?

We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.

By MedCity News